Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)

Next Previous
Trial Profile

Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Talazoparib (Primary) ; ZEN 3694 (Primary)
  • Indications Breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms ComBET

Most Recent Events

  • 06 May 2025 Planned End Date changed from 4 Aug 2025 to 31 Dec 2026.
  • 06 May 2025 Planned primary completion date changed from 4 Aug 2025 to 31 Dec 2026.
  • 08 Sep 2022 Planned End Date changed from 8 Jul 2025 to 4 Aug 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top